Table 1.
Characteristics of Participating Transplant Centers.
| Characteristic | Finland (n = 2) |
Sweden (n = 1) |
France (n = 10) |
Total (n = 13) |
|---|---|---|---|---|
| Type of transplant center, n (%) 1 | ||||
| Academic/university | 2 (100.0) | 1 (100.0) | 8 (80.0) | 11 (84.6) |
| Public | 1 (50.0) | 0 | 6 (60.0) | 7 (53.8) |
| Specialized cancer center | 0 | 0 | 1 (10.0) | 1 (7.7) |
| Physicians dedicated to HSCT (≥90% of the time), median (Q1, Q3), n | 3.5 (3.0, 4.0) | 3.0 (3.0, 3.0) | 4.5 (3.0, 7.0) | 4.0 (3.0, 5.0) |
| Adult HSCTs conducted (1 January 2016–30 June 2017), median (Q1, Q3), n | 95.5 (76.0, 115.0) | 53.0 (53.0, 53.0) | 94.0 (70.0, 120.0) | 91.0 (70.0, 115.0) |
| Criteria used to grade aGVHD, n (%) 1 | ||||
| MAGIC | 1 (50.0) | 0 | 2 (20.0) | 3 (23.1) |
| Original Glucksberg | 0 | 0 | 6 (60.0) | 6 (46.2) |
| Modified Glucksberg or Keystone | 1 (50.0) | 1 (100.0) | 5 (50.0) | 7 (53.8) |
| IBMTR | 0 | 0 | 1 (10.0) | 1 (7.7) |
| Other | 0 | 0 | 1 (10.0) | 1 (7.7) |
| Patients with severe (grades III/IV) aGVHD after allogeneic HSCT, median (Q1, Q3), % | 34.3 (18.5, 50.0) | 25.0 (25.0, 25.0) | 30.0 (30.0, 50.0) | 30.0 (30.0, 50.0) |
aGVHD, acute graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; IBMTR, International Bone Marrow Transplant Registry; MAGIC, Mount Sinai Acute GVHD International Consortium.1 Categories are not mutually exclusive.